ClinicalTrials.gg
CompletedNCT07570082Updated Aug 19, 2026

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

A Phase 1 interventional study of Atumelnant and Carbamazepine in Healthy Volunteers, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.

Read the detailed description

This is a Phase 1, open-label, two-Cohort Study to assess the effect of a strong CYP3A4 inducer on the pharmacokinetics of atumelnant and the effect of atumelnant on the pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in healthy participants.

Approximately 20 healthy male and female participants adult male and female (of non-childbearing potential) participants will be enrolled in Cohort 1. Approximately 26 healthy male and female participants adult male and female (of non-childbearing potential) participants will be enrolled in Cohort 2.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
  • CRN04894
  • Atumelnant
03

In context

Lead sponsor

Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult females of non- (Section 14.2) or healthy adult males, 19-55 years of age, inclusive, at the screening visit.
  2. ≥18.0 and ≤32.0 kg/m2 at the screening visit.
  3. Is willing and able to comply with all study procedures and restrictions, including fasting and consumption of protocol-specified standardized meal for required study measurements; inpatient admission; follow-up contact; receipt of rescue therapy, if necessary; abstinence from tobacco, alcohol, drugs, and from strenuous unaccustomed exercise and sports (defined as greater than 30 minutes per day) during the study period.
  4. Normal adrenocorticotropic hormone (ACTH)-stimulated cortisol test at the screening visit and does not have signs and symptoms of adrenal insufficiency as deemed by the PI or designee.

Exclusion criteria

Exclusion Criteria:

  1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.
  3. Female participant with a positive pregnancy test at the screening visit or at first check-in or who is lactating.
  4. Female participant of .
  5. Had prior treatment with atumelnant.
  6. Participation in another clinical study within 30 days or received any drug within 5 half-lives prior to the first dosing, whichever is longer. The time window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study.
  7. History or presence of or idiosyncratic reaction to the study interventions or related compounds.
  8. Has a blood loss ≥500 mL or donated blood within 3 months prior to the first dosing.
  9. Unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, vitamin supplements, or other food supplements within 14 days or 5 half-lives prior to the first dosing, whichever is longer.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Cohort 1

    atumelnant, carbamazepine (CYP3A4 Inducer)

    Drug: Atumelnant · Drug: Carbamazepine

  • Experimental
    Cohort 2

    atumelnant, midazolam (CYP3A4 substrate), digoxin (P-gp substrate), metformin (MATE1/2-K substrate)

    Drug: Atumelnant · Drug: Midazolam · Drug: Digoxin · Drug: Metformin

Interventions

  • Atumelnant, tablets

    Also known as: CRN04894

  • DrugCarbamazepine

    CYP3A4 inducer

  • DrugMidazolam

    CYP3A4 substrate

  • DrugDigoxin

    P-gp substrate

  • DrugMetformin

    MATE1/2-K substrate

06

What researchers measure

Primary outcomes

  1. Cohort 1: Pharmacokinetics (AUC 0-last)

    Time frame: Up to Day 34

  2. Cohort 1: Pharmacokinetics (AUC 0-inf)

    Time frame: Up to Day 34

  3. Cohort 1: Pharmacokinetics (Cmax)

    Time frame: Up to Day 34

  4. Cohort 2: Pharmacokinetics (AUC 0-last)

    Time frame: Up to Day 21

  5. Cohort 2: Pharmacokinetics (AUC 0-inf)

    Time frame: Up to Day 21

  6. Cohort 2: Pharmacokinetics (Cmax)

    Time frame: Up to Day 21

Secondary outcomes

  1. Cohort 1: Number of participants with Treatment Emergent Adverse Events

    Time frame: Up to Day 34

  2. Cohort 2: Number of participants with Treatment Emergent Adverse Events

    Time frame: Up to Day 21

07

Study locations

1 site
  • Crinetics Study Site
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jun 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 6, 2026
StartActual
May 28, 2026
Primary completionActual
Jun 30, 2026
CompletionActual
Jul 30, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570082
Responsible party
Sponsor
First posted
May 6, 2026
Start date
May 28, 2026
Primary completion
Jun 30, 2026
Completion
Jul 30, 2026
Last update
Aug 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atumelnant

Start the discussion